ConductScience.org, home

Paper40468460

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.

Li H and 11 others. Acta Neuropathol Commun, 2025. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. Papers, record 40468460. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40468460

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.
PubMed
Journal
Acta Neuropathol Commun
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
14.14, provisional
iCite
Revised in PubMed
2025-06-27
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li HHengzeng
2Wu YYahui
3Chen YYue
4Lv JJinquan
5Qu CChengkang
6Mei TTingjie
7Zheng YYunfan
8Ye CCheng
9Li FFeifei
10Ge SShuo
11Yao AAnhui
12Jia LLiyun

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
TemozolomideMajor topic
Drug Resistance, NeoplasmMajor topic
GliomaMajor topic
Brain NeoplasmsMajor topic
Antineoplastic Agents, AlkylatingMajor topic
Humans
Animals
Tumor Microenvironment

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
YNZX2024005research project of 988th Hospital of Joint Logistic Support Force of PLAPubMed
LHGJ20230703the joint construction project of Henan ProvincePubMed
KFJJ23-09Mthe opening project of State Key Laboratory of Explosion Science and Technology (Beijing Institute of Technology)PubMed

Source PubMed

Download CSV of grants

References533

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136755314Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.J Nanobiotechnology2023https://conductscience.org/library/papers/36755314PubMed
238724526Glioma.Nat Rev Dis Primers2024https://conductscience.org/library/papers/38724526PubMed
339544152BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu-Modified GSH-Responsive Nanoparticles.Adv Sci (Weinh)2024https://conductscience.org/library/papers/39544152PubMed
437382632Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.Cancer Immunol Immunother2023https://conductscience.org/library/papers/37382632PubMed
535836243PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.J Exp Clin Cancer Res2022https://conductscience.org/library/papers/35836243PubMed
632641768Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.Nat Commun2020https://conductscience.org/library/papers/32641768PubMed
738981438Multi-scale signaling and tumor evolution in high-grade gliomas.Cancer Cell2024https://conductscience.org/library/papers/38981438PubMed
832973101A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma.Mol Cancer Res2021https://conductscience.org/library/papers/32973101PubMed
936195821Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.Pharm Res2022https://conductscience.org/library/papers/36195821PubMed
1031263673C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage.Front Oncol2019https://conductscience.org/library/papers/31263673PubMed
1139170552Navigating the neurological frontier: Macromolecular marvels in overcoming blood-brain barrier challenges for advanced drug delivery.Heliyon2024https://conductscience.org/library/papers/39170552PubMed
1232872164Fatty Acid Synthase: An Emerging Target in Cancer.Molecules2020https://conductscience.org/library/papers/32872164PubMed
1330506499Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.J Neurooncol2019https://conductscience.org/library/papers/30506499PubMed
1439567689Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma.Nature2024https://conductscience.org/library/papers/39567689PubMed
1535205750PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.Cancers (Basel)2022https://conductscience.org/library/papers/35205750PubMed
1634305910Immune Checkpoint Inhibitors in Human Glioma Microenvironment.Front Immunol2021https://conductscience.org/library/papers/34305910PubMed
1737178737Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.Gastroenterology2023https://conductscience.org/library/papers/37178737PubMed
1835760272Nanomedicine for glioblastoma: Progress and future prospects.Semin Cancer Biol2022https://conductscience.org/library/papers/35760272PubMed
1931601097Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.ACS Appl Mater Interfaces2019https://conductscience.org/library/papers/31601097PubMed
2034696786Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34696786PubMed

See all 533 referencesDownload CSV of references

Cited by48

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42983003Ex vivo therapy-driven selection of glioblastoma stem-like cells models resistance evolution.EMBO Mol Med2026https://conductscience.org/library/papers/42983003PubMed
42965578Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy.J Neurooncol2026https://conductscience.org/library/papers/42965578PubMed
42964232Pathology-guided multimodal transformer predicts postoperative survival benefit from adjuvant chemotherapy in glioma: from DNA damage repair to immune characterization.Front Immunol2026https://conductscience.org/library/papers/42964232PubMed
42939568Anticancer Effects of Genistein and Its Interaction with Temozolomide in Human Melanoma, Neuroblastoma and Glioblastoma Cells.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42939568PubMed
42909908Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics.Front Oncol2026https://conductscience.org/library/papers/42909908PubMed
42848143Characterization and Selective Antiglioma Activity of a Standardized Hydroalcoholic Extract from Yellow Psidium cattleianum Fruits.Neurochem Res2026https://conductscience.org/library/papers/42848143PubMed
42830602Redundant mispair excision mechanisms in eukaryotic DNA mismatch repair.Nucleus2026https://conductscience.org/library/papers/42830602PubMed
42801660PLOD1 Catalytic Activity Stabilizes ENO1 by Limiting FBXW7-dependent Degradation to Promote Glycolysis and TMZ Resistance in Glioblastoma.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42801660PubMed
42797315Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation.Pharmaceutics2026https://conductscience.org/library/papers/42797315PubMed
42698858Research progress on glioma drug resistance: mechanism analysis and therapeutic strategies.Front Pharmacol2026https://conductscience.org/library/papers/42698858PubMed
42667153Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42667153PubMed
42653658Association Between Temozolomide Resistance and Long Non-Coding RNA Expression Profiles in Glioblastoma Cell Lines.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42653658PubMed
4260954820(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation.Front Med (Lausanne)2026https://conductscience.org/library/papers/42609548PubMed
42602314Correlative study of Parnassia palustris extract on orthotopic glioma suppression and gut microbiota modulation in mice.Front Microbiol2026https://conductscience.org/library/papers/42602314PubMed
42589514Peptide-Based Nanocomplexes Enable Transferrin-Mediated Uptake and p53-Driven Antitumor Activity in 2D and 3D Glioblastoma Models.Int J Mol Sci2026https://conductscience.org/library/papers/42589514PubMed
42579188Stem-like characteristics across sequentially temozolomide-adapted glioblastoma cell populations with increasing levels of acquired resistance.Mol Biol Rep2026https://conductscience.org/library/papers/42579188PubMed
42516804Systems biology of Wnt signaling in glioma chemotherapy resistance: Integrating multi-omics mechanisms and emerging therapeutic vulnerabilities (Review).Oncol Lett2026https://conductscience.org/library/papers/42516804PubMed
42505361The Hallmarks of Glioblastoma: Functional Interplay Between Long Non-Coding RNAs and RNA-Binding Proteins.Cells2026https://conductscience.org/library/papers/42505361PubMed
42491242Reconstructing the glioblastoma microenvironment in heterotypic 3D spheroids: a multicellular model to study tumor-stromal crosstalk.Front Bioeng Biotechnol2026https://conductscience.org/library/papers/42491242PubMed
42445436Complement system-related gene signatures implicated in the recurrence of glioma.Transl Cancer Res2026https://conductscience.org/library/papers/42445436PubMed

See all 48 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MGMT4255PubTator's text mininghttps://conductscience.org/library/genes/4255

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40468460

GET https://conductscience.org/api/papers/v1/40468460/references?page=2